Drug Discovery용 AI 시장 규모, 점유율, 동향 분석 보고서 : 용도별, 치료 영역별, 최종 용도별, 지역별, 부문별 예측(2026-2033년)
Artificial Intelligence In Drug Discovery Market Size, Share & Trends Analysis Report By Application, By Therapeutic Area, By End Use, By Region, And Segment Forecasts, 2026 - 2033
상품코드:1941434
리서치사:Grand View Research
발행일:2026년 01월
페이지 정보:영문 100 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
Drug Discovery용 AI시장 요약
세계의 Drug Discovery용 AI시장 규모는 2025년 23억 5,000만 달러로 추정되며, 2033년까지 137억 7,000만 달러에 이를 것으로 예측됩니다.
또한 2026-2033년 연평균 복합 성장률(CAGR) 24.8%를 나타낼 것으로 예측됩니다. 비용 효율적인 의약품 개발에 대한 수요 증가, 의약품 재사용에 대한 임상시험 증가, 만성 질환의 유병률 증가는 시장 성장에 기여하는 중요한 요인입니다.
또한, 정밀의료와 표적치료제 개발에 대한 관심 증가, 컴퓨팅 능력과 클라우드 인프라의 개선도 시장 성장을 가속하는 요인으로 작용하고 있습니다. 비용 효율적인 의약품 개발 전략에 대한 수요 증가는 신약 개발 산업에서 AI의 성장을 크게 견인하고 있습니다. 2025년 10월 'Frontiers in Pharmacology'지에 게재된 논문에 따르면, 기존의 신약개발은 10년 이상의 장기적인 타임라인이 필요하며, 약품 1개당 비용은 20억 달러가 넘는 경우가 많습니다. 신약 개발 및 적응증 외 사용에 있어 AI는 승인되었거나 임상시험 중인 약물을 새로운 적응증에 집중함으로써 초기 단계의 안전성 시험을 피할 수 있는 전략을 제공합니다. 약물 전환은 위험을 줄이고, 평균 3억 달러의 투자로 3-12년이라는 단기간에 시장에 출시할 수 있을 것으로 예측됩니다.
AI는 방대한 생물학적, 화학적, 임상적 데이터를 빠르게 분석하여 약물과 질병의 새로운 연관성을 찾아냄으로써 이 과정을 가속화합니다. 이를 통해 개발 기간과 비용을 절감하고, 제약사 및 의료 서비스 제공업체에게 신약 개발에 대한 경제적으로 실현 가능한 대안을 제시합니다. AI와 약물 전환을 통합하여 생산성을 향상시키는 동시에 관련 위험과 투자를 줄이고 업계의 주요 과제를 효과적으로 해결할 수 있습니다. AI는 광범위한 화학물질 라이브러리, 생의학 문헌, 오믹스 데이터 세트, 실제 증거를 효율적으로 분석하여 광범위한 경험적 스크리닝을 지원하는 대신 한정된 고확률 후보를 식별함으로써 이러한 경제적 이점을 더욱 강화합니다.
목차
제1장 조사 방법과 범위
제2장 주요 요약
제3장 Drug Discovery용 AI 시장 변수, 동향, 범위
제4장 Drug Discovery용 AI 시장 : 용도별 추정 및 동향 분석
제5장 Drug Discovery용 AI 시장 : 치료 영역별 추정 및 동향 분석
제6장 Drug Discovery용 AI 시장 : 최종 용도별 추정 및 동향 분석
제7장 Drug Discovery용 AI 시장 : 지역별 추정 및 동향 분석
제8장 경쟁 구도
LSH
영문 목차
영문목차
Artificial Intelligence In Drug Discovery Market Summary
The global artificial intelligence in drug discovery market size was estimated at USD 2.35 billion in 2025 and is projected to reach USD 13.77 billion by 2033, growing at a CAGR of 24.8% from 2026 to 2033. The rising demand for cost-effective drug development, the increasing number of clinical trials in drug repurposing, and the growing prevalence of chronic diseases are significant factors contributing to market growth.
In addition, the growing focus on precision medicine and targeted drug development, as well as improvements in computing power and cloud infrastructure, are other factors fueling market growth. The rising demand for cost-effective drug development strategies substantially drives the growth of artificial intelligence (AI) in the drug discovery industry. According to an article published in the Frontiers in Pharmacology Journal in October 2025, Traditional drug discovery involves lengthy timelines, often exceeding a decade, and costs frequently exceed USD 2 billion per drug. AI in drug discovery and repurposing offers a strategy to bypass early-stage safety testing by focusing on approved or investigational drugs for new indications. Drug repurposing is anticipated to reduce risks and bring drugs to the market in 3-12 years, with an average investment of USD 300 million.
AI accelerates this process by rapidly analyzing extensive biological, chemical, and clinical datasets to identify novel associations between drugs and diseases. This reduces development timelines and costs, offering pharmaceutical companies and healthcare providers an economically viable alternative to the development of new drugs. Integrating artificial intelligence with drug repurposing effectively addresses key industry challenges by enhancing productivity while reducing associated risks and investments. AI enhances this economic advantage by efficiently analyzing extensive chemical libraries, biomedical literature, omics datasets, and real-world evidence to identify a limited set of high-probability candidates, rather than supporting broad empirical screening.
Global Artificial Intelligence In Drug Discovery Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global artificial intelligence in drug discovery market report based on application, therapeutic area, end use, and region.
Application Outlook (Revenue, USD Million, 2021 - 2033)
Drug optimization and repurposing
Preclinical testing
Others
Therapeutic Area Outlook (Revenue, USD Million, 2021 - 2033)
Oncology
Neurodegenerative Diseases
Cardiovascular Disease
Metabolic Diseases
Infectious Disease
Others
End Use Outlook (Revenue, USD Million, 2021 - 2033)
Pharmaceutical & Biotechnology Companies
Contract Research Organizations (CROs)
Academic & Research Institutes
Others
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
China
Japan
India
South Korea
Australia
Thailand
Latin America
Brazil
Argentina
MEA
South Africa
Saudi Arabia
UAE
Kuwait
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Market Definitions
1.2.1. Application Segment
1.2.2. Therapeutic Area
1.2.3. End Use
1.3. Information analysis
1.3.1. Market formulation & data visualization
1.4. Data validation & publishing
1.5. Information Procurement
1.5.1. Primary Research
1.6. Information or Data Analysis
1.7. Market Formulation & Validation
1.8. Market Model
1.9. Total Market: CAGR Calculation
1.10. Objectives
1.10.1. Objective 1
1.10.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Insights Landscape
Chapter 3. Artificial Intelligence in Drug Discovery Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Rising demand for cost-effective drug development
3.2.1.2. Increasing clinical trials in drug repurposing
3.2.1.3. Growing focus on precision medicine and targeted drug development
3.2.2. Market restraint analysis
3.2.2.1. Highly regulated industry
3.2.2.2. High computational costs and infrastructure requirements
3.2.3. Market opportunity analysis
3.2.4. Market challenges analysis
3.3. Case Study Insights
3.4. Artificial Intelligence in Drug Discovery Market Analysis Tools
3.4.1. Industry Analysis - Porter's
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
3.4.2.4. Environmental Landscape
3.4.2.5. Legal Landscape
3.4.2.6. Social Landscape
Chapter 4. Artificial Intelligence in Drug Discovery Market: Application Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Global Artificial Intelligence in Drug Discovery Market Application Movement Analysis
4.3. Global Artificial Intelligence in Drug Discovery Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
4.4. Drug optimization and repurposing
4.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
4.5. Preclinical testing
4.5.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
4.6. Others
4.6.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
Chapter 5. Artificial Intelligence in Drug Discovery Market: Therapeutic Area Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Global Artificial Intelligence in Drug Discovery Market Therapeutic Area Movement Analysis
5.3. Global Artificial Intelligence in Drug Discovery Market Size & Trend Analysis, by Therapeutic Area, 2021 to 2033 (USD Million)
5.4. Oncology
5.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
5.5. Neurodegenerative Diseases
5.5.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
5.6. Cardiovascular Disease
5.6.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
5.7. Metabolic Diseases
5.7.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
5.8. Infectious Disease
5.8.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
5.9. Others
5.9.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
Chapter 6. Artificial Intelligence in Drug Discovery Market: End Use Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Global Artificial Intelligence in Drug Discovery Market End Use Movement Analysis
6.3. Global Artificial Intelligence in Drug Discovery Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
6.4. Pharmaceutical & Biotechnology Companies
6.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
6.5. Contract Research Organizations (CROs)
6.5.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
6.6. Academic and Research Institutes
6.6.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
6.7. Other
6.7.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
Chapter 7. Artificial Intelligence in Drug Discovery Market: Regional Estimates & Trend Analysis
7.1. Regional Market Share Analysis, 2025 & 2033
7.2. Regional Market Dashboard
7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
7.4. North America
7.4.1. U.S.
7.4.1.1. Key country dynamics
7.4.1.2. Regulatory framework
7.4.1.3. Competitive scenario
7.4.1.4. U.S. market estimates and forecasts, 2021 to 2033 (USD Million)
7.4.2. Canada
7.4.2.1. Key country dynamics
7.4.2.2. Regulatory framework
7.4.2.3. Competitive scenario
7.4.2.4. Canada market estimates and forecasts, 2021 to 2033 (USD Million)
7.4.3. Mexico
7.4.3.1. Key country dynamics
7.4.3.2. Regulatory framework
7.4.3.3. Competitive scenario
7.4.3.4. Mexico market estimates and forecasts, 2021 to 2033 (USD Million)
7.5. Europe
7.5.1. UK
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework
7.5.1.3. Competitive scenario
7.5.1.4. UK market estimates and forecasts, 2021 to 2033 (USD Million)
7.5.2. Germany
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework
7.5.2.3. Competitive scenario
7.5.2.4. Germany market estimates and forecasts, 2021 to 2033 (USD Million)
7.5.3. France
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework
7.5.3.3. Competitive scenario
7.5.3.4. France market estimates and forecasts, 2021 to 2033 (USD Million)
7.5.4. Italy
7.5.4.1. Key country dynamics
7.5.4.2. Regulatory framework
7.5.4.3. Competitive scenario
7.5.4.4. Italy market estimates and forecasts, 2021 to 2033 (USD Million)
7.5.5. Spain
7.5.5.1. Key country dynamics
7.5.5.2. Regulatory framework
7.5.5.3. Competitive scenario
7.5.5.4. Spain market estimates and forecasts, 2021 to 2033 (USD Million)
7.5.6. Norway
7.5.6.1. Key country dynamics
7.5.6.2. Regulatory framework
7.5.6.3. Competitive scenario
7.5.6.4. Norway market estimates and forecasts, 2021 to 2033 (USD Million)
7.5.7. Sweden
7.5.7.1. Key country dynamics
7.5.7.2. Regulatory framework
7.5.7.3. Competitive scenario
7.5.7.4. Sweden market estimates and forecasts, 2021 to 2033 (USD Million)
7.5.8. Denmark
7.5.8.1. Key country dynamics
7.5.8.2. Regulatory framework
7.5.8.3. Competitive scenario
7.5.8.4. Denmark market estimates and forecasts, 2021 to 2033 (USD Million)
7.6. Asia Pacific
7.6.1. Japan
7.6.1.1. Key country dynamics
7.6.1.2. Regulatory framework
7.6.1.3. Competitive scenario
7.6.1.4. Japan market estimates and forecasts, 2021 to 2033 (USD Million)
7.6.2. China
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework
7.6.2.3. Competitive scenario
7.6.2.4. China market estimates and forecasts, 2021 to 2033 (USD Million)
7.6.3. India
7.6.3.1. Key country dynamics
7.6.3.2. Regulatory framework
7.6.3.3. Competitive scenario
7.6.3.4. India market estimates and forecasts, 2021 to 2033 (USD Million)
7.6.4. Australia
7.6.4.1. Key country dynamics
7.6.4.2. Regulatory framework
7.6.4.3. Competitive scenario
7.6.4.4. Australia market estimates and forecasts, 2021 to 2033 (USD Million)
7.6.5. South Korea
7.6.5.1. Key country dynamics
7.6.5.2. Regulatory framework
7.6.5.3. Competitive scenario
7.6.5.4. South Korea market estimates and forecasts, 2021 to 2033 (USD Million)
7.6.6. Thailand
7.6.6.1. Key country dynamics
7.6.6.2. Regulatory framework
7.6.6.3. Competitive scenario
7.6.6.4. Thailand market estimates and forecasts, 2021 to 2033 (USD Million)
7.7. Latin America
7.7.1. Brazil
7.7.1.1. Key country dynamics
7.7.1.2. Regulatory framework
7.7.1.3. Competitive scenario
7.7.1.4. Brazil market estimates and forecasts, 2021 to 2033 (USD Million)
7.7.2. Argentina
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework
7.7.2.3. Competitive scenario
7.7.2.4. Argentina market estimates and forecasts, 2021 to 2033 (USD Million)
7.8. MEA
7.8.1. South Africa
7.8.1.1. Key country dynamics
7.8.1.2. Regulatory framework
7.8.1.3. Competitive scenario
7.8.1.4. South Africa market estimates and forecasts, 2021 to 2033 (USD Million)
7.8.2. Saudi Arabia
7.8.2.1. Key country dynamics
7.8.2.2. Regulatory framework
7.8.2.3. Competitive scenario
7.8.2.4. Saudi Arabia market estimates and forecasts, 2021 to 2033 (USD Million)
7.8.3. UAE
7.8.3.1. Key country dynamics
7.8.3.2. Regulatory framework
7.8.3.3. Competitive scenario
7.8.3.4. UAE market estimates and forecasts, 2021 to 2033 (USD Million)
7.8.4. Kuwait
7.8.4.1. Key country dynamics
7.8.4.2. Regulatory framework
7.8.4.3. Competitive scenario
7.8.4.4. Kuwait market estimates and forecasts, 2021 to 2033 (USD Million)
